Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: brain cancer + study results + drug  Related to the article below (Last Update: 5/13/2008)

Start of Phase II Clinical Study for Rabies Monoclonal Antibody ...
FOXBusiness -
Crucell's proprietary MAbstract(R) technology can be used to discover drug targets, such as cancer markers or proteins from infectious agents including ...CRXL - OTC:CMTX
Thallion Receives Health Canada Approval to Initiate Phase II for ...
FOXBusiness -
The Company expects to be in a position to release preliminary data from an interim analysis of the trial in late 2008, with results from the entire study ...TSE:TLN - OTC:CMTX
A Mother's Worst Fear
Tampa Tribune, FL - May 10, 2008
Preliminary results - NOT CANCER. Ecstatic doesn't begin to cover our reaction. But our happiness was short lived. If not cancer, then what was going on? ...
YM Biosciences Reports Fiscal Third Quarter 2008 Operational and ...
PharmaLive.com (press release), PA - May 9, 2008
Preliminary results are expected in mid 2008 from the 59 patients in the first of two possible tranches of YM's Phase II colorectal cancer study. ...YMI
Preliminary Results from Phase 2 Genzyme Study Highlight Potential ...
FOXBusiness - May 7, 2008
These preliminary results are consistent with results observed for patients beginning enzyme replacement therapy. The analysis showed that drug-related ...GENZ
New health center opens
North County Times, CA - May 11, 2008
4S RANCH ---- A four-class cancer prevention and survival cooking course will be offered from 6-8 pm Thursdays now through May 22 at Jimbo's. ...

eFluxMedia
Bad news on Rituxan for Genentech
San Francisco Chronicle,  USA - Apr 29, 2008
Shares in Genentech Inc. sagged Tuesday, after the company said its blockbuster cancer drug Rituxan failed to curb symptoms of the debilitating autoimmune ...
HGS Stock Falls as Rivals' Lupus Drug Fails Washington Post
all 165 news articles »  HGSI - DNA
Clinical Briefs
U.S. Medicine, DC - May 8, 2008
"Our work identifies the mechanism by which seizures increase production of a drug transport protein in the blood brain barrier, known as P-glycoprotein, ...
High-fat ketogenic diet gives relief from seizures
Los Angeles Times, CA - May 9, 2008
It did so more dramatically than the diabetes drug metformin. The results, published in the New England Journal of Medicine in 2002, were so pronounced that ...
Blocked Brain Enzyme Decreases Appetite And Promotes Weight Loss
Science Daily (press release) - May 6, 2008
"We believe we have identified an important drug development target that could potentially turn into a metabolic triple play: appetite control, ...
Source: Google News

… Chemotherapy with Carmustine-loaded Polymers for High-grade Gliomas: A Randomized Double-blind Study … -
S Valtonen, U Timonen, P Toivanen, H Kalimo, L … - Neurosurgery, 1997 - neurosurgery-online.com
... Controlled release polymers for drug delivery in the brain. Cancer Res 53:329-333,
1993 ... be stopped prematurely because of the unavailability of the study drug. ...

… medical history in brain tumour development. Results from the international adult brain tumour study -
B Schlehofer, M Blettner, S Preston-Martin, D … - International Journal of Cancer, 1999 - doi.wiley.com
... in the Swedish component of the study and in ... schizophrenia, multiple sclerosis,
toxoplasmosis, cancer of sites ... 2 years before diagnosis of the brain tumour (or ...

Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. -
C Christodoulou, D Bafaloukos, P Kosmidis, E … - Annals of Oncology, 2001 - pt.wkhealth.com
... solid tumors were entered into the study from May ... with SCLC, 4 patients with breast
cancer, 2 patients ... All patients (n = 28) had brain metastases, with the ...

… and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European … -
T Le Chevalier, D Brisgand, JY Douillard, JL Pujol … - Journal of Clinical Oncology, 1994 - jco.ascopubs.org
... agent docetaxel or vinorelbine at progression: final results of a ... JP Pignon Benefits
of Adding a Drug to a ... From the German and Swiss Lung Cancer Study Group J ...

… : efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central … -
MR Fetell, SA Grossman, JD Fisher, B Erlanger, E … - Journal of Clinical Oncology, 1997 - jco.ascopubs.org
... AN Nafziger, and MR Fetell Randomized study of Paclitaxel ... implications for the treatment
of metastatic brain tumors. ... Cancer Res., October 1, 2006; 12(19): 5770 ...

… anticancer drug S-1 (1M tegafur?0.4 M gimestat?1M otastat potassium) in advanced gastric cancer … -
Y Sakata, A Ohtsu, N Horikoshi, K Sugimachi, Y … - European Journal of Cancer, 1998 - Elsevier
... hypersensitivity, serious complications, symptoms attributable to brain metastasis
and active secondary cancer. ... were not permitted to enrol in the study. ...

… Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study … -
MJ van den Bent, MJB Taphoorn, AA Brandes, J … - Journal of Clinical Oncology, 2003 - jco.ascopubs.org
... O, Boogerd W, et al: EORTC Brain Tumor Group ... recurrent oligodendroglioma after
PCV-chemotherapy?A phase II study. ... Clin Cancer Res 7:839?845, 2001 [Abstract ...

… First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen … -
J Bonneterre, B Thurlimann, JFR Robertson, M … - Journal of Clinical Oncology, 2000 - jcojournal.org
... status could be included in the study. ... therapy for advanced breast cancer, extensive
visceral disease (significant hepatic involvement, brain metastases, and ...

… vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer … -
JL Finlay, JM Boyett, AJ Yates, JH Wisoff, JM … - Journal of Clinical Oncology, 1995 - jco.ascopubs.org
... Edwards, J. Rabbitt, M. Malec, and MD Prados Phase II study of 6 ... as a diagnostic
and prognostic marker for primary human brain tumors Neuro ... Home page, Cancer Res. ...

… Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern … -
P Bonomi, KM Kim, D Fairclough, D Cella, J Kugler, … - Journal of Clinical Oncology, 2000 - jcojournal.org
... in the single-agent trials, a phase III study was designed ... disease, with the exception
of skin cancer or carcinoma ... in-situ of the cervix; and no brain metastases ...

Source: Google Scholar

Drug study for brain cancer shows promising results

DETROIT – A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

The randomized Phase II study focused on patients with glioblastoma multiforme (GBM), whose cancer had recurred after first- or second-line therapy. The study revealed that more than a third who were treated with Avastin (bevacizumab) alone, as well as more than half of those treated with Avastin in combination with the chemotherapy drug irinotecan, lived without further progression of the disease for a period of six months. In addition, no new or unexpected adverse effects from the use of Avastin were observed during the study.

“This is very encouraging news,” says Tom Mikkelsen, M.D., a neuro-oncologist who is the study’s principal investigator at Henry Ford and co-director of the Hermelin Brain Tumor Center. "Historical estimates suggest that only 15 percent of patients with this aggressive type of brain cancer live without their cancer progressing within six months. Although gliomas [fast-growing malignant brain tumors] are nearly always incurable, use of a drug like Avastin may help to buy precious time for patients, as well as to preserve their physical and mental functions longer than was previously possible.”

Avastin is a therapeutic antibody designed to inhibit Vascular Endothelial Growth Factor (VEGF), a protein that stimulates development of new blood vessels in a process known as angiogenesis, while maintaining existing tumor vessels. By binding to VEGF, Avastin acts as an anti-angiogenesis agent that chokes off the blood supply to tumors, which in turn inhibits their growth and metastasis.

The national study is sponsored by Genentech and Henry Ford Hospital is one of the large study sites.

“The same process that makes gliomas so deadly may turn out to be exactly the same thing that makes it possible to slow down their progression,” Dr. Mikkelsen says. "This is a very significant advance in the battle to control these aggressive tumors because it could lead to treatment options where none existed previously for patients with recurrent disease.”

Previously Avastin had been used in combination with chemotherapy as a first-line treatment for metastatic colorectal cancer and lung cancer. Because of its demonstrated success rate with these cancers, Avastin currently is being studied worldwide in more than 300 clinical trials for 20 different tumor types.

“With currently approved therapies, the chances of suppressing GBM are poor at less than 10 percent,” says Dr. Mikkelsen. “This type of targeted therapy using Avastin may prove to be the best new hope we have for helping patients with recurrent disease who previously had few options available to them.”

According to the American Cancer Society (ACS), the five-year survival rate for patients with GBM is 3 percent, a figure that has not changed in more than 25 years. The ACS estimates there will be 20,500 new cases of brain cancer and 12,740 brain cancer deaths in 2007.

###
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.